INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 155 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $391,448,590 | -18.6% | 7,514,851 | -1.0% | 0.01% | -15.4% |
Q2 2023 | $480,666,361 | +22.1% | 7,591,067 | +4.4% | 0.01% | +8.3% |
Q1 2023 | $393,607,252 | -0.2% | 7,268,832 | -2.4% | 0.01% | 0.0% |
Q4 2022 | $394,262,519 | +19.3% | 7,450,161 | +4.9% | 0.01% | +9.1% |
Q3 2022 | $330,459,000 | -17.9% | 7,102,050 | +0.8% | 0.01% | -15.4% |
Q2 2022 | $402,320,000 | +1.6% | 7,048,357 | +8.9% | 0.01% | +18.2% |
Q1 2022 | $395,924,000 | +32.2% | 6,470,417 | +13.1% | 0.01% | +37.5% |
Q4 2021 | $299,476,000 | +40.0% | 5,721,766 | -0.3% | 0.01% | +33.3% |
Q3 2021 | $213,852,000 | -8.4% | 5,736,396 | +0.3% | 0.01% | 0.0% |
Q2 2021 | $233,443,000 | +11.7% | 5,718,849 | -7.1% | 0.01% | 0.0% |
Q1 2021 | $208,946,000 | +11.4% | 6,158,133 | +4.4% | 0.01% | 0.0% |
Q4 2020 | $187,575,000 | +38.7% | 5,898,568 | +11.9% | 0.01% | +20.0% |
Q3 2020 | $135,285,000 | +5.3% | 5,272,216 | +5.3% | 0.01% | 0.0% |
Q2 2020 | $128,528,000 | +88.4% | 5,006,942 | +12.8% | 0.01% | +66.7% |
Q1 2020 | $68,209,000 | -49.2% | 4,437,785 | +13.5% | 0.00% | -40.0% |
Q4 2019 | $134,169,000 | +351.6% | 3,910,511 | -1.7% | 0.01% | +400.0% |
Q3 2019 | $29,708,000 | -41.8% | 3,977,031 | +1.1% | 0.00% | -50.0% |
Q2 2019 | $51,055,000 | +8.9% | 3,933,274 | +2.2% | 0.00% | 0.0% |
Q1 2019 | $46,884,000 | +2.8% | 3,849,211 | -3.9% | 0.00% | 0.0% |
Q4 2018 | $45,614,000 | -46.5% | 4,004,666 | +1.9% | 0.00% | -50.0% |
Q3 2018 | $85,243,000 | +27.1% | 3,928,310 | +3.5% | 0.00% | +33.3% |
Q2 2018 | $67,058,000 | -15.1% | 3,794,986 | +1.1% | 0.00% | -25.0% |
Q1 2018 | $79,004,000 | +36.3% | 3,753,130 | -6.2% | 0.00% | +33.3% |
Q4 2017 | $57,962,000 | +11.5% | 4,002,920 | +21.5% | 0.00% | 0.0% |
Q3 2017 | $51,977,000 | +9.1% | 3,293,872 | -14.1% | 0.00% | 0.0% |
Q2 2017 | $47,641,000 | -18.0% | 3,835,751 | +7.3% | 0.00% | 0.0% |
Q1 2017 | $58,093,000 | +25950.7% | 3,574,983 | +24047.1% | 0.00% | – |
Q4 2016 | $223,000 | +3.2% | 14,805 | +4.2% | 0.00% | – |
Q3 2016 | $216,000 | -94.7% | 14,215 | -86.3% | 0.00% | -100.0% |
Q2 2016 | $4,038,000 | +41.6% | 104,029 | +1.4% | 0.01% | +20.0% |
Q1 2016 | $2,852,000 | -47.8% | 102,574 | +1.0% | 0.01% | -37.5% |
Q4 2015 | $5,461,000 | +17.5% | 101,526 | -12.5% | 0.01% | +14.3% |
Q3 2015 | $4,646,000 | +272.0% | 116,014 | +196.6% | 0.01% | +250.0% |
Q2 2015 | $1,249,000 | -46.3% | 39,114 | -59.8% | 0.00% | -33.3% |
Q1 2015 | $2,324,000 | +35.4% | 97,314 | 0.0% | 0.00% | +50.0% |
Q4 2014 | $1,717,000 | +28.7% | 97,314 | 0.0% | 0.00% | 0.0% |
Q3 2014 | $1,334,000 | -24.8% | 97,314 | -7.5% | 0.00% | -33.3% |
Q2 2014 | $1,774,000 | -6.9% | 105,214 | +0.4% | 0.00% | 0.0% |
Q1 2014 | $1,905,000 | – | 104,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |